Undervalued compared to fair value. Biogen had a net margin of 35.63% and a return on equity of 51.00%. The biotechnology company reported $4.58 earnings per share for the quarter, missing the Zacks' consensus estimate of … The average number of shares traded each day over the past 30 days, The ratio of current share price to trailing twelve month EPS that signals if the price is high or low compared to other stocks, The ratio of annual dividend to current share price that estimates the dividend return of a stock, A score provided by CDP (formerly the Carbon Disclosure Project) that rates a company on its climate transparency and performance. Stock analysis for Biogen Inc (BIIB:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Is Biogen undervalued compared to its fair value and its price relative to the market? Citi Research analyst Mohit Bansal downgraded Biogen stock (ticker: BIIB) to Sell from Neutral, and set a new target price of $240. The institutional investor owned 4,629 shares of the biotechnology company’s stock after acquiring an additional 2,010 shares during the period. Subscribe to Premium to view Fair Value for BIIB. Valuation. View Biogen Inc. BIIB investment & stock information. For my risk tolerance, Biogen is still too much of a gamble. Alliancebernstein L.P. boosted its holdings in Biogen Inc. (NASDAQ:BIIB) by 2.2% during the 4th quarter, according to its most recent disclosure with the SEC. [7] In May 2006, the company announced it would acquire … The institutional investor owned 4,113 shares of the biotechnology company’s stock after selling 599 shares during the period. But Clarivate analysts … Find the latest Biogen Inc. (BIIB) stock quote, history, news and other vital information to help you with your stock trading and investing. Veritable L.P.’s holdings in Biogen … The U.S. Food and Drug Administration (FDA) will soon decide the fate of the company's investigational Alzheimer's drug. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. A valuation method that multiplies the price of a company's stock by the total number of outstanding shares. 3 weeks ago | Simply Wall St Jesus Mantas Is The Independent Director of Biogen Inc. (NASDAQ:BIIB) And They Just Picked Up 44% More Shares No, BIIB has not paid a dividend within the past 12 months. The biotechnology company had revenue of $2.85 billion for the quarter, compared to analyst estimates of $2.80 billion. QQQ 310.88. (NASDAQ: BIIB) Biogen stock price per share is $266.49 today (as of Mar 9, 2021). By contrast, DOW inherits 0.8185% risk (volatility on return distribution) over the 30 days horizon. Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Tuesday, February 2nd. You can buy Biogen cheaper than Warren Buffett did! M&T Bank Corp lowered its position in shares of Biogen Inc. (NASDAQ:BIIB) by 5.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. The fund owned 786 shares of the biotechnology company’s stock after purchasing an additional 120 shares during the […] The company inherits 1.8194% risk (volatility on return distribution) over the 30 days horizon. Find the latest historical data for Biogen Inc. Common Stock (BIIB) at Nasdaq.com. Stock analysis for Biogen Inc (BIIB:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Alliancebernstein L.P. owned approximately 0.18% of Biogen … M&T Bank Corp’s holdings in Biogen … If you had invested in Biogen stock … With its stock down 14% over the past three months, it is easy to disregard Biogen (NASDAQ:BIIB). D.A. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). There are no changes to Alkermes' existing ratings including the Ba3 Corporate Family Rating, the Ba3-PD Probability of Default Rating, Ba3 (LGD3) senior secured rating, or the SGL-1 Speculative Grade Liquidity Rating. Free forex prices, toplists, indices and lots more. The stock, trading at around $280 this week, has traded between $223.25 and $363.92 over the past 52 weeks. Get the latest Biogen Inc (BIIB) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Biogen Inc Stock Dividend Yield & Dates Add to Watchlist. If you want to know who really controls Biogen Inc. (NASDAQ:BIIB), then you'll have to look at the makeup of its share registry. The biotechnology company reported $4.58 EPS for the quarter, missing the Zacks' consensus estimate of $4.87 by ($0.29). W e believe that Biogen stock (NASDAQ: BIIB), a biotechnology company focused on treatments for neurological diseases, is a good buying opportunity at the present time. NASDAQ:BIIB - Biogen Stock Price Target and Predictions. :) The Oracle of Omaha picked up 648,447 shares of Biogen , allocating 0.08% of the equity portfolio to the holding. Alliancebernstein L.P. owned approximately 0.18% of Biogen worth $67,820,000 at the end […] The firm owned 6,785 shares of the biotechnology company’s stock after selling 4,149 shares during the quarter. Should you be buying BIIB stock or one of its competitors? All rights reserved. Veritable L.P. trimmed its holdings in Biogen Inc. (NASDAQ:BIIB) by 12.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. D.A. Biogen (NASDAQ: BIIB) does not pay a dividend. Biogen (NASDAQ: BIIB) does not pay a dividend. GE, AerCap join air leasing businesses in $30 billion deal. But if you pay close attention, you might gather that its strong financials could mean … Biogen (NASDAQ:BIIB) is facing its biggest moment ever. What is the 52 week high and low for Biogen (NASDAQ: BIIB)? Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock … Man sues Hertz over receipt that cleared him of murder. View Biogen Inc. BIIB investment & stock information. BIIB | Complete Biogen Inc. stock news by MarketWatch. During the quarter, the stock traded for an average price of $279.04 per share. Alliancebernstein L.P. boosted its holdings in Biogen Inc. (NASDAQ:BIIB) by 2.2% during the 4th quarter, according to its most recent disclosure with the SEC. What is Biogen's Market Cap? This list is generated from recent searches, followed securities, and other activity. Back in June, a judge invalidated a patent on Tecfidera, which is the biotech's … Biopharmaceutical concern Biogen Inc (NASDAQ:BIIB) is up 7.9% to trade at $291.00 this morning, after the Food and Drug Administration (FDA) extended the review period for Biogen's experimenta... Investors Business Daily - 1 month ago View real-time stock prices and stock quotes for a full financial overview. (NASDAQ: BIIB) Biogen's 52-week high was $363.92, and its 52-week low was $223.25. How much is Biogen's dividend? During the quarter, the stock traded for … … View real-time stock prices and stock quotes for a full financial overview. Twin Capital Management Inc. lessened its position in shares of Biogen Inc. (NASDAQ:BIIB) by 2.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange … Biogen Dividends FAQ. Biogen (NASDAQ:BIIB) Price Target and Consensus Rating MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock … Which company executives are buying and selling shares of Biogen (NASDAQ:BIIB) stock? Biogen (NASDAQ:BIIB) last released its earnings results on Tuesday, February 2nd. Shares fell 1.3% to 266.49 on today's stock market. Sawtooth Solutions LLC’s holdings in Biogen were worth $1,661,000 as of its most recent SEC filing. The company had revenue of $2.85 billion for the quarter, compared to analyst estimates of $2.80 billion. Biogen Inc. (NASDAQ:BIIB) posted its earnings results on Tuesday, February, 2nd. The business had revenue of $2.85 billion for the quarter, compared to analysts' expectations of $2.80 billion. BIIB | Complete Biogen Inc. stock news by MarketWatch. NASDAQ:BIIB - Biogen Inc (US) | Quote and Chart | Investagrams {{UserNav.UserFreeTrial.IsEligibleForPrimeFreeTrial ? Should You Use Biogen's (NASDAQ:BIIB) Statutory Earnings To Analyse It? Find the latest analyst research for Biogen Inc. Common Stock (BIIB) at Nasdaq.com. Biogen (NASDAQ:BIIB) is a large-cap biotech that has witnessed significant volatility this year, with over 40% price swings in both directions. Biogen (NASDAQ:BIIB) hasn't had the best year -- and not necessarily because of the COVID-19 pandemic. Biogen stock is a component of several stock indices such as the S&P 100, S&P 500, S&P 1500, and NASDAQ-100 and the company is listed on the NASDAQ stock exchange under the ticker symbol, BIIB. Overview Forecast Earnings Dividend. :) The Oracle of Omaha picked up 648,447 shares of Biogen , allocating 0.08% of the equity portfolio to the holding. Competitors Biogen (NASDAQ:BIIB) Vs. AMGN, GILD, VRTX, REGN, ALXN, and SGEN. Get the latest Biogen Inc (BIIB) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Get the latest Biogen Inc. BIIB detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. S&P 500 3,939.34 (+1.04%) Shares have lost about 1.4% in that time frame, outperforming the S&P 500. Biogen Inc. Common Stock (BIIB) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. MUFG Americas Holdings Corp increased its position in Biogen Inc. (NASDAQ:BIIB) by 76.7% in the fourth quarter, HoldingsChannel.com reports. Is Biogen Inc. (NASDAQ:BIIB) Trading At A 43% Discount? Veritable L.P.’s holdings in Biogen were worth $1,007,000 as of […] S&P 500 3,898.81. View BIIB's most recent analyst ratings, analyst estimates and price targets at MarketBeat. The fund owned 70,440 shares of the biotechnology company’s stock after selling 3,785 shares during the period. The institutional investor owned 4,113 shares of the biotechnology company’s stock after selling 599 shares during the period. Two drug companies that have made brain science their mission -- Biogen (NASDAQ:BIIB) and Sage Therapeutics (NASDAQ: ... For Biogen, a company whose stock is down 17% year to date, it … Davidson & CO. lessened its position in shares of Biogen Inc. (NASDAQ:BIIB) by 12.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. Biogen Inc (BIIB) - Stock, Realtime Charts, Screeners, News, Price Alerts and Many More. Biogen (NASDAQ:BIIB) is a large-cap biotech that has witnessed significant volatility this year, with over 40% price swings in both directions. The biotechnology company reported $4.58 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $4.87 by ($0.29). Veritable L.P. trimmed its holdings in Biogen Inc. (NASDAQ:BIIB) by 12.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Biogen Inc. (NASDAQ:BIIB) posted its earnings results on Tuesday, February, 2nd. It has been about a month since the last earnings report for Biogen Inc. (BIIB). What is Biogen … Biogen revenue declined rapidly in Q4 2020. Target and Analyst Ratings; Price Target History; Upgrades and Downgrades; About; FAQ; Consensus Rating: Hold; Consensus Price Target: $304.47; Forecasted Upside: 14.25 %; Number of Analysts: 32; Breakdown: 5 Sell Ratings; 15 Hold Ratings; 12 Buy Ratings; 0 Strong Buy Ratings $ 266.49 As of 03/9/2021 01:00 AM ET -3.52 (-1.30%) 1 … , Biogen Stock: Why A Key Medicine Could Shoot To Blockbuster Status By 2025. Analysts Expect Approval. … The biotechnology company reported $4.58 earnings per share for the quarter, missing the consensus estimate of $4.87 by ($0.29). Biogen had a return on equity of 51.00% and a net margin of 35.63%. NASDAQ:BIIB - Biogen Stock Price Target and Predictions. The biotechnology company reported $4.58 earnings per share for the quarter, missing analysts' consensus estimates of $4.87 by $0.29. Currency in USD, Trade prices are not sourced from all markets. MUFG Americas Holdings Corp’s holdings in Biogen were worth $1,133,000 at the end of the most […] Back in June, a judge invalidated a patent on … The news comes days before the company is scheduled to release further data on a potential Alzheimer’s disease therapy, called donanmeab. DOW 32,297.02. Davidson & CO. lessened its position in shares of Biogen Inc. (NASDAQ:BIIB) by 12.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. With its stock down 14% over the past three months, it is easy to disregard Biogen (NASDAQ:BIIB). With Biogen stock trading at $266.49 per share, the total value of Biogen stock (market capitalization) is $41.01B. Rating Action: Moody's assigns Ba3 to Alkermes' term loan; stable outlookGlobal Credit Research - 08 Mar 2021New York, March 08, 2021 -- Moody's Investors Service ("Moody's") assigned a Ba3 rating to the new senior secured term loan of Alkermes, Inc., a subsidiary of Alkermes plc (collectively "Alkermes"). Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. 41.7% . Find the latest Biogen Inc. (BIIB) stock quote, history, news and other vital information to help you with your stock trading and investing. You can buy Biogen cheaper than Warren Buffett did! The firm owned 276,975 shares of the biotechnology company’s stock after buying an additional 5,955 shares during the period. Biogen stock is a component of several stock indices such as the S&P 100, S&P 500, S&P 1500, and NASDAQ-100 and the company is listed on the NASDAQ stock exchange under the ticker symbol, BIIB. Target and Analyst Ratings; Price Target History; Upgrades and Downgrades; About; FAQ; Consensus Rating: Hold; Consensus Price Target: $306.13; Forecasted Upside: 14.21 %; Number of Analysts: 33; Breakdown: 5 Sell Ratings; 15 Hold Ratings; 13 Buy Ratings; 0 Strong Buy Ratings $ 268.04 As of 01/11/2021 04:55 PM ET +15.5 (6.14%) 1 … Raymond James analyst Steven Seedhouse downgraded the stock … Investors who bought shares of Biogen (NASDAQ:BIIB) in 2010 or earlier and held onto them have plenty of reason to smile; Biogen has gained more than 390% since 2010. Biogen stock has yo-yoed on these news items. The firm owned 276,975 shares of the biotechnology company’s stock after buying an additional 5,955 shares during the period. The average Biogen stock price prediction forecasts a potential downside of N/A from the current BIIB share price of $263.57. Biogen (BIIB) stock price, charts, trades & the US's most popular discussion forums. Sawtooth Solutions LLC reduced its stake in Biogen Inc. (NASDAQ:BIIB) by 37.9% during the fourth quarter, HoldingsChannel.com reports. Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Biogen, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals … Does Biogen pay a dividend? © 2021 Verizon Media. The firm had revenue of $2.85 billion during the quarter, compared to the consensus estimate of $2.80 billion. Get the latest Biogen Inc. BIIB detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. What is Biogen's Dividend Payment Date? The fund owned 2,175 shares of the biotechnology company’s stock after selling 301 shares during the quarter. The difference between the high and low prices over the past day, The difference between the high and low prices over the past 52 weeks. Biogen historical daily return volatility represents how much Biogen stock's price daily returns swing around its mean daily price change - it is a statistical measure of its dispersion of returns. D.A. Biogen had a net margin of 35.63% and a return on equity of … A controversial Alzheimer's drug that has weighed on Biogen stock this year could ultimately become a major blockbuster within five years, a market research group predicted Tuesday. View the most recent insider trading activity for BIIB stock at MarketBeat. Biogen (NASDAQ:BIIB) last issued its earnings results on Tuesday, February 2nd. Tecfidera generic competition will worsen in 2021. Biogen's stock is trading at a price-to-earnings (P/E) ratio of 11, which is cheap compared to the Health Care Select Sector SPDR Fund, where the average holding trades at a P/E of 25. What predictions are top-rated research analysts making about Biogen (NASDAQ:BIIB)? Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGS - NasdaqGS Real Time Price. Biogen (NASDAQ:BIIB) hasn't had the best year -- and not necessarily because of the COVID-19 pandemic. Last year, its … Ownership. The fund owned 2,175 shares of the biotechnology company’s stock … Share Price vs. Fair Value. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Biogen stock was originally listed at a price of $5.73 in Dec 31, 1997 . What is BIIB's earnings growth forecast for 2021-2023? It is currently -26.77% from its 52-week high and 19.37% from its 52-week low. Rowland & Co. Investment Counsel ADV lifted its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 18.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. Two drug companies that have made brain science their mission -- Biogen (NASDAQ:BIIB) and Sage Therapeutics (NASDAQ: SAGE)-- announced on … BIIB stock … … Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. A high-level overview of Biogen Inc. (BIIB) stock.